https://www.selleckchem.com/pr....oducts/i-bet151-gsk1
There were 57 trials (39% ) focused on long-term disease modifying therapies, with the remaining 88 trials (61% ) focused on therapies for symptomatic relief. A total of 50 (34% ) trials were testing repurposed therapies. There is a broad pipeline of both symptomatic and disease modifying therapies currently being tested in clinical trials for PD. There is a broad pipeline of both symptomatic and disease modifying therapies currently being tested in clinical trials for PD.Chronic sleep restriction promotes neuroinflammation
Like
Comment
Share
